In a multicentre cohort study of 88 patients with renal cell carcinoma and brain metastases, the intracranial response rate was 55% in the cohort of patients with progressing brain metastases without concomitant treatment with brain-directed local therapy. 

The results showed that cabozantinib demonstrated significant intracranial activity and an acceptable safety profile in patients with renal cell carcinoma and brain metastases. 

The results of the BREAKPOINT trial have concluded that cabozantinib following IO-IO or IO-TKI therapy showed promising efficacy and was well tolerated. However, in this study, adverse event-related treatment delays were seen in 53.5% of patients, and dose reductions were needed for about 48% of patients. 

Reference

1. Hirsch L, et al.  JAMA Oncol. Published October 21, 2021. DOI: 10.1001/jamaoncol.2021.4544.
2. Christopher JD Wallis. Urologic Oncology Fellow, Vanderbilt University Medical Care Centre at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, Virtual Annual Meeting, June4-8, 2021.